Good break down. Perhaps it might be important to consider, tabulate and interpret the results of the ABL Covid study (if it ever happens) in those 3 phases of infection in addition to the overall aggregate? Of course we could end up with our old friend, a failed study for pre-specified end points, but we learned a lot again. Just looking for the day where we actually know what we can prove that is beneficial, and actually prove it!

What a weird world we love in .... we have a drug that nearly EVERYONE (including FDA) seems to know works for various things to some benficial degree, but we cannot seem to prove it in a meaningful accepted study, and seem to be getting stone walled at every turn.

In this recent revelation, it appears/sounds if it may not be wise to introduce ABL in recent known Covid infections, and that the ACE2 inhibition may be past its benefit at that stage unless the patient is already on ABL for another indication which involves weakend subjects with diabetic/coronary/renal dysfunction for some side benefit prophylaxis. However, perhaps ABL would still be useful later on for those patients, in reducing cytokine storms and longer term damage in those patients.

Did I get that right, or even close? ... ohhhh what to do with this wonder drug? Figure it out some day, hopefully. If it ever happens, interested to see what the Covid study results look like, and wish we could the time clock ticking on what looks on paper to be a good looking BoM2 study opportunity.